Volume 68, Issue 5, Pages (November 2005)

Slides:

Advertisements

Similar presentations

Volume 54, Pages S135-S139 (December 1998)

Advertisements

Volume 54, Issue 2, Pages (August 1998)

Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells Y. Huang, N.A. Noble, J. Zhang, C. Xu, W.A.

Plasma sodium and hypertension

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Viper venom for diabetic nephropathy

Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation Anil K. Bidani, M.D., Karen A. Griffin,

Volume 12, Issue 5, Pages (November 2010)

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Volume 61, Issue 4, Pages (April 2002)

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Volume 54, Issue 2, Pages (August 1998)

Glomerulus number and blood pressure in the Prague hypertensive rat

Volume 64, Issue 2, Pages (August 2003)

The renal sympathetic and renin-angiotensin response to lower body negative pressure in well-compensated cirrhosis Florence Wong*, Kenneth Sniderman‡,

The intrarenal renin-angiotensin system in hypertension

Hiroyuki Kobori, Lisa M. Harrison-Bernard, L. Gabriel Navar

Volume 63, Issue 3, Pages (March 2003)

Volume 80, Issue 9, Pages (November 2011)

Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency Fiona E. Mackie, Timothy W. Meyer,

Volume 74, Issue 3, Pages (August 2008)

Steven J. Rosansky, Richard J. Glassock Kidney International

Volume 81, Issue 3, Pages (February 2012)

Volume 63, Issue 2, Pages (February 2003)

Volume 54, Issue 5, Pages (November 1998)

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Fernando Elijovich, Cheryl L. Laffer Kidney International

Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension A. Davenport, C. Cox, R. Thuraisingham Kidney.

Volume 75, Issue 2, Pages (January 2009)

Volume 86, Issue 5, Pages (November 2014)

Volume 68, Issue 6, Pages (December 2005)

Volume 361, Issue 9352, Pages (January 2003)

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

Volume 78, Issue 8, Pages (October 2010)

David M. Charytan, John P. Forman Kidney International

Special deLIVERy: podocyte injury promotes renal angiotensin II generation from liver- derived angiotensinogen David I. Ortiz-Melo, Robert F. Spurney

Angiotensin-(1–7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells Z. Su, J. Zimpelmann, K.D. Burns Kidney.

Volume 67, Issue 1, Pages (January 2005)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Role of endothelin and nitric oxide imbalance in the pathogenesis of hypoxia-induced arterial hypertension Zhenmin Ni, Shahrooz Bemanian, Salah D. Kivlighn,

Volume 65, Issue 6, Pages (June 2004)

Angiotensin II production and distribution in the kidney – II

The kidney, a cardiovascular risk marker, and a new target for therapy

Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats Quaisar Ali,

Neurogenic factors and hypertension in renal disease

Volume 54, Pages S135-S139 (December 1998)

Volume 62, Pages S47-S52 (December 2002)

Volume 57, Issue 2, Pages (October 2000)

Renal phenotype of low kallikrein rats

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Carmine Zoccali, Francesca Mallamaci Kidney International

The course of the remnant kidney model in mice

Volume 73, Issue 5, Pages (March 2008)

Aldosterone in the development and progression of renal injury

Organ transplantation goes to the movies

Volume 62, Issue 4, Pages (October 2002)

Changbin Qiu, Chris Baylis Kidney International

Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension Julian Segura, Carlos Campo, Luis M. Ruilope Kidney.

Volume 64, Issue 4, Pages (October 2003)

Is complement a target for therapy in renal disease?

Volume 62, Issue 5, (November 2002)

Volume 76, Issue 9, Pages (November 2009)

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications

T cells and T-cell receptors in acute renal failure

Volume 58, Issue 6, Pages (December 2000)

Volume 57, Issue 2, Pages (October 2000)

Volume 65, Issue 2, Pages (February 2004)

Antonio Piccoli, Luana Pillon Kidney International

Presentation transcript:

Volume 68, Issue 5, Pages 2189-2196 (November 2005) Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors Carlos M. Ferrario, Jewell Jessup, Patricia E. Gallagher, David B. Averill, K. Bridget Brosnihan, E. Ann Tallant, Ronald D. Smith, Mark C. Chappell Kidney International Volume 68, Issue 5, Pages 2189-2196 (November 2005) DOI: 10.1111/j.1523-1755.2005.00675.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Group averages of tail-cuff systolic blood pressure determinations in conscious Lewis normotensive rats before and after the completion of 2 weeks of oral administration of vehicle, lisinopril, losartan, or both drugs in combination. Values are means ± SE. *P < 0.05 compared to their respective value before initiation of the medications. P value within graph denotes statistical difference between rats medicated with losartan or combination therapy. Kidney International 2005 68, 2189-2196DOI: (10.1111/j.1523-1755.2005.00675.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Effects of the various treatments on urinary excretion rates of angiotensin I (Ang I), angiotensin II (Ang II), and angiotensin-(1-7) [Ang-(1-7)]. B is baseline. Values are means ± SE. *P < 0.05 compared to the corresponding baseline values; **P < 0.05 compared to animals medicated with lisinopril. Kidney International 2005 68, 2189-2196DOI: (10.1111/j.1523-1755.2005.00675.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 Effects of the various treatments on angiotensin-converting enzyme (ACE)2 activity measures determined as the rate of angiotensin-(1-7) [Ang-(1-7)] formation from angiotensin II (Ang II) in renal membranes isolated from the kidney cortex. Values are means ± SE. *P < 0.05 compared to the vehicle group. Kidney International 2005 68, 2189-2196DOI: (10.1111/j.1523-1755.2005.00675.x) Copyright © 2005 International Society of Nephrology Terms and Conditions